Microfluidic Dose Synthesis Card for On-Site Radiopharmaceutical Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current systems for producing radiopharmaceuticals for PET imaging require centralized production due to the need for large quantities and stringent quality control, which limits the use of short-lived isotopes and increases transportation-related decay, making it difficult for hospitals to produce and administer these radiopharmaceuticals efficiently and effectively.
Innovation Solution
A compact, low-power cyclotron and microfluidic chemical production module that allows for on-site production of radiopharmaceuticals, combined with a sample card and quality control module for rapid testing, enabling the production and administration of approximately ten unit doses of radiopharmaceuticals, including short-lived isotopes like carbon-11, and reducing the time and resources required for quality control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If centralized production facilities are used to synthesize radiopharmaceuticals in large quantities, then quality control can be ensured, but transportation time increases causing significant radioactive decay and loss of active isotopes
Solution Approach 1:
The production system is segmented into a centralized production facility that synthesizes radiopharmaceuticals and distributes them to multiple satellite production modules at hospitals. Each satellite module can perform final processing and quality control locally, reducing transportation time for the actual product while maintaining centralized oversight for bulk synthesis quality assurance.
Solution Approach 2:
Radiopharmaceuticals are synthesized in advance at centralized facilities and stored in controlled conditions with minimal delay. The system performs preliminary quality control testing at the production facility before shipment, so that upon arrival at satellite modules, final administration-ready processing can occur immediately without extended transportation or waiting time.
2Quantity of substance
If large quantities of radiopharmaceuticals are synthesized before transport, then sufficient doses can be delivered to remote locations, but a large portion of radioisotopes decay during transport reducing efficiency
Solution Approach 1:
The system transitions from a single centralized production model to a distributed network model with multiple satellite production modules at different geographic locations. This dimensional change in production architecture allows radiopharmaceuticals to be produced closer to end-users, reducing transportation distance and radioactive decay while maintaining sufficient supply to remote locations through the distributed network.
Solution Approach 2:
The system changes the parameter of production location from centralized to distributed, and adjusts production quantities at each node based on local demand. Satellite modules produce smaller quantities locally that don't require long-distance transport, thereby minimizing radioactive decay while still providing sufficient doses to remote areas through the distributed production network.
3Quantity of substance
If conventional cyclotrons are used for radioisotope production, then sufficient radioisotopes can be produced, but the machines are large requiring great physical space and radiation shielding
Solution Approach 1:
The system replaces conventional mechanical cyclotrons with alternative radioisotope production methods such as generator systems (e.g., Mo-99/Tc-99m generators) or linear accelerators that are more compact. These substituted systems produce sufficient radioisotopes for PET imaging while requiring significantly less physical space and radiation shielding infrastructure, enabling placement within hospital facilities.
4Quantity of substance
If conventional cyclotrons are used for radioisotope production, then sufficient radioisotopes can be produced, but the machines require great commitments of radiation shielding and cost
Solution Approach 1:
The system substitutes conventional cyclotrons with generator-based production systems or compact linear accelerators that produce radioisotopes with lower radiation output or more favorable decay characteristics. These substituted systems require reduced radiation shielding and have simpler infrastructure requirements while maintaining sufficient radioisotope production capacity for PET imaging applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This solution enables immediate administration of radiopharmaceuticals, reduces waste, and allows for the use of a wider range of isotopes, improving the efficiency and effectiveness of PET imaging by minimizing transportation-related decay and streamlining quality control processes.
Implementation Method 1
Cyclotrons operate by accelerating electrically-charged particles along outward, quasi-spherical orbits to a predetermined extraction energy generally on the order of millions of electron volts. The high-energy electrically-charged particles form a continuous beam that travels along a predetermined path and bombards a target. When the bombarding particles interact in the target, a nuclear reaction occurs at a sub-atomic level, resulting in the production of a radioisotope.
Implementation Method 2
A positron-emitting radioisotope undergoes radioactive decay, whereby its nucleus emits positrons. In human tissue, a positron inevitably travels less than a few millimeters before interacting with an electron, converting the total mass of the positron and the electron into two photons of energy. The photons are displaced at approximately 180 degrees from each other, and can be detected simultaneously as 'coincident' photons on opposite sides of the human body.
Data Source
AI summary
Microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, ten (10) unit doses of radiopharmaceutical biomarker for use in positron emission tomography (PET). A radioisotope from an accelerator or other radioisotope generator is introduced into a reaction vessel, along with organic and aqueous reagents, and the mixture heated to synthesize a solution of a pre-selected radiopharmaceutical. The solution is purified by passing through a combination of solid phase extraction purification components, trap and release components, and a filter. The synthesis process reduces waste and allows for production of biomarker radiopharmaceuticals on site and close to the location where the unit dose will be administered to the patient. On-site, as-needed production of radiopharmaceuticals in small doses reduces the time between synthesis of the radiopharmaceutical and administration of that radiopharmaceutical, minimizing loss of active isotopes through decay and allowing production of lesser amounts of radioisotopes overall.